The Biologics News and Reports Portal

Show Cart

La Merie Publishing

Results 41 - 60 of 188

Jul 2018 Adenosine Pathway Modulation via A2AR, CD39 & CD73 – Target Pipeline List 07/2018

100.00 €

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

500.00 €

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

500.00 €

Jun 2018 R&D Drug Pipeline Database: 1-Year Subscription

6,000.00 €

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

600.00 €

Jun 2018 Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

810.00 €

1,350.00 €

(Discount: 40.00%)

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

150.00 €

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

400.00 €

Shopping cart

Cart empty

Latest report

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Featured Products

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Latest Target Pipeline

STING Agonists & Antagonists

Shopping cart

Cart empty

Latest report

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Featured Products

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

La Merie Publishing

Jul 2018 Adenosine Pathway Modulation via A2AR, CD39 & CD73 – Target Pipeline List 07/2018

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Jul 2018 CD27 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 ICOS Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 PD-1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 PD-L1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 CTLA-4 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 LAG-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIM-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIGIT Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 B7-H3 Immune Checkpoint Inhibitors - Target Pipeline List 07/2018

Jul 2018 CD40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 GITR Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 OX40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

Jun 2018 R&D Drug Pipeline Database: 1-Year Subscription

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Jun 2018 Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing